459 related articles for article (PubMed ID: 34907821)
1. Advances with pharmacotherapy for the treatment of interstitial lung disease.
Comes A; Sgalla G; Perrotta A; Richeldi L
Expert Opin Pharmacother; 2022 Mar; 23(4):483-495. PubMed ID: 34907821
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
3. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and management of cough in interstitial lung disease.
Rasheed AZ; Metersky ML; Ghazal F
Expert Rev Respir Med; 2023 Dec; 17(12):1177-1190. PubMed ID: 38159067
[TBL] [Abstract][Full Text] [Related]
5. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
6. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
Sarkar P; Avram C; Chaudhuri N
Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
[TBL] [Abstract][Full Text] [Related]
7. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
8. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
9. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
10. The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.
Puiu R; Motoc NS; Lucaciu S; Ruta MV; Rajnoveanu RM; Todea DA; Man MA
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540667
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Approach to Adult Fibrotic Lung Diseases.
Adegunsoye A; Strek ME
Chest; 2016 Dec; 150(6):1371-1386. PubMed ID: 27521738
[TBL] [Abstract][Full Text] [Related]
13. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs).
Joannes A; Voisin T; Morzadec C; Letellier A; Gutierrez FL; Chiforeanu DC; Le Naoures C; Guillot S; De Latour BR; Rouze S; Jaillet M; Crestani B; Wollin L; Jouneau S; Vernhet L
Pulm Pharmacol Ther; 2023 Dec; 83():102267. PubMed ID: 37972706
[TBL] [Abstract][Full Text] [Related]
14. Interstitial Lung Disease: A Review.
Maher TM
JAMA; 2024 May; 331(19):1655-1665. PubMed ID: 38648021
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).
Spagnolo P; Distler O; Ryerson CJ; Tzouvelekis A; Lee JS; Bonella F; Bouros D; Hoffmann-Vold AM; Crestani B; Matteson EL
Ann Rheum Dis; 2021 Feb; 80(2):143-150. PubMed ID: 33037004
[TBL] [Abstract][Full Text] [Related]
16. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
17. Progressive fibrotic interstitial lung disease.
Pereira CAC; Cordero S; Resende AC
J Bras Pneumol; 2023; 49(5):e20230098. PubMed ID: 37610955
[TBL] [Abstract][Full Text] [Related]
18. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
19. Current perspective of progressive-fibrosing interstitial lung disease.
Kishaba T
Respir Investig; 2022 Jul; 60(4):503-509. PubMed ID: 35431170
[TBL] [Abstract][Full Text] [Related]
20. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
Markart P; Drakopanagiotakis F; Wygrecka M
Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]